Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study

20250 citationsJournal Articlegold Open Access

Authors

François Villeret · Hôpital de la Croix-Rousse

Mohamed Bouattour · Hôpital Beaujon

Jean‐Frédéric Blanc · Hôpital Cardiologique du Haut-Lévêque

Jean-Marie Péron · Centre Hospitalier Universitaire de Toulouse

Marilyne Debette‐Gratien · Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine

Pierre Nahon · Assistance Publique – Hôpitaux de Paris

Eric Nguyen Khac

Abstract

In CLERANCE, tolerability and efficacy of cabozantinib were similar to those observed in CELESTIAL. We obtained more details in the management of cabozantinib doses, identified surrogate markers of better outcome, and underlined prolonged overall survival for patients able to undergo subsequent lines.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver physiology and pathology Cholangiocarcinoma and Gallbladder Cancer Studies

Publication Details

Published in: Liver Cancer

DOI: 10.1159/000549076

Field-Weighted Citation Impact: 0.00

Command Palette

Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study

Authors

Abstract

Topics & Keywords

Publication Details